| 宋笑天,徐 帅,白 槟,余鹏飞,赵青川.RNA特异性腺苷脱氨酶1在胃癌中的表达及其临床意义[J].现代生物医学进展英文版,2024,(6):1007-1013. |
| RNA特异性腺苷脱氨酶1在胃癌中的表达及其临床意义 |
| Expression of Adenosine Deaminase Acting on RNA 1 in Gastric Cancer and its Clinical Significance |
| Received:November 21, 2023 Revised:December 18, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.06.002 |
| 中文关键词: ADAR1 胃癌 表达 预后 |
| 英文关键词: ADAR1 Gastric Cancer Expression Prognosis |
| 基金项目:国家自然科学基金项目（82100680） |
|
| Hits: 436 |
| Download times: 296 |
| 中文摘要: |
| 摘要 目的：检测ADAR1在胃癌患者中的表达情况，探讨ADAR1的表达水平对胃癌患者的潜在临床意义。方法：通过基因表达谱数据交互分析（GEPIA）数据库获得了胃癌和正常胃组织样本ADAR1在mRNA水平的表达差异情况，在170例胃癌患者的胃癌和配对组织芯片中，通过免疫组织化学手段检测ADAR1的表达情况，并分析ADAR1的表达和临床特征之间的关系。通过癌症基因组图谱（TCGA）数据库获得胃癌的RNAseq数据（level3）和相应的临床信息，用于分析ADAR1与临床诊疗过程中的潜在相关性。通过Kaplan-Meier Plotter平台获得ADAR1的表达对胃癌患者的预后分析预测，结合组织芯片的评分和临床预后资料进行分析、验证。结果：ADAR1在胃癌组织中异常高表达，差异具有统计学意义（P＜0.0001）；其高表达与胃癌的组织学分化程度相关（P=0.044）；性别（HR=2.082，95 % CI=1.160-3.736，P=0.014）、淋巴结肿大（HR=1.582，95 % CI=1.003-2.496，P=0.049）是影响胃癌患者总生存期的独立危险因素；高表达ADAR1的患者总生存期更短，预后差；ADAR1的表达和肿瘤突变负荷（TMB）呈正相关（P=0.002），具有评估胃癌患者免疫治疗价值的潜力。结论：ADAR1在胃癌中异常高表达，具有较大的判断患者预后与评估免疫治疗价值的潜力，有希望成为一个新型的临床诊疗靶标。 |
| 英文摘要: |
| ABSTRACT Objective: In this study, we aimed to observe the expression of ADAR1 in gastric cancer patients and to determine the role of ADAR1 and underlying the potential clinical significance of ADAR1 in gastric cancer. Methods: Through the GEPIA database, we found differences in the expression of ADAR1 at the mRNA level between gastric cancer and normal gastric tissue samples. In the gastric cancer and paired tissues of 170 gastric cancer patients collected at Xijing Hospital, we verified this difference through immunohistochemistry and analyzed the relationship between the expression of ADAR1 and pathological features. Through the Kaplan-Meier Plotter platform and the TCGA database, we analyzed the impact of ADAR1 expression on the prognosis of gastric cancer patients. Results: ADAR1 was abnormally high expressed in gastric cancer. Moreover, the results showed that the high expression of ADAR1 was related to histological differentiation of gastric cancer (P=0.044). Gender (HR=2.082 95 % CI=1.160-3.736, P=0.014), and lymph node enlargement (HR=1.582, 95 % CI=1.003-2.496, P=0.049), which were independent risk factors affecting the overall survival of gastric cancer patients. We also found that the expression of ADAR1 was positively correlated with tumor mutation burden (TMB) (P=0.002), indicating potential value in assessing the immunotherapeutic value of gastric cancer patients. In addition, patients with high expression of ADAR1 had a shorter overall survival and poor prognosis. Conclusion: The high expression of ADAR1 in gastric cancer may have the potential to judge prognosis and assess the value of immunotherapy, and is expected to become a new clinical diagnostic and therapeutic target. |
|
View Full Text
View/Add Comment Download reader |
| Close |
